Predictable and sustainable engraftment of live biotherapeutic products into the human gut microbiome is being explored as a promising way to modulate the human gut microbiome. We utilize a synbiotic approach pairing the infant gut microbe Bifidobacterium longum subspecies infantis (B. infantis) and human milk oligosaccharides (HMO). B. infantis, which is typically absent in adults, engrafts into healthy adult microbiomes in an HMO-dependent manner at a relative abundance of up to 25% of the bacterial population without antibiotic pretreatment or adverse effects. Corresponding changes in metabolites are detected. Germ-free mice transplanted with dysbiotic human microbiomes also successfully engraft with B. infantis in an HMO-dependent manner, and the synbiotic augments butyrate levels both in this in vivo model and in in vitro cocultures of the synbiotic with specific Firmicutes species. Finally, the synbiotic inhibits the growth of enteropathogens in vitro. Our findings point to a potential safe mechanism for ameliorating dysbioses characteristic of numerous human diseases.

正在探索将活的生物治疗产品以可预测和可持续的方式植入人体肠道微生物组，作为调节人体肠道微生物组的一种有前途的方法。我们利用一种合生元方法将婴儿肠道微生物长双歧杆菌婴儿亚种( B. infantis )和人乳寡糖 (HMO) 配对。乙。婴儿通常不存在于成人中，它以 HMO 依赖性方式以高达 25% 的细菌种群的相对丰度移植到健康的成人微生物群中，而无需抗生素预处理或副作用。检测到代谢物的相应变化。移植了失调的人类微生物组的无菌小鼠也成功地移植了B. infantis以 HMO 依赖性方式，并且在该体内模型和合生元与特定厚壁菌门物种的体外共培养中，合生元增加了丁酸盐水平。最后，合生元在体外抑制肠道病原体的生长 。我们的研究结果指出了一种潜在的安全机制，可以改善多种人类疾病的生态失调特征。